LMN 101
Alternative Names: LMN-101Latest Information Update: 28 Oct 2023
At a glance
- Originator Lumen Bioscience
- Class Antibacterials; Recombinant proteins
- Mechanism of Action Bacterial protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Campylobacter infections
- No development reported Traveller's diarrhoea
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Traveller's-diarrhoea in USA (PO, Capsule)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Traveller's-diarrhoea(Prevention, In volunteers) in Australia (PO, Capsule)
- 04 Oct 2022 Lumen Bioscience completes a phase II trial Campylobacter infections (Prevention) in USA (PO, Capsules) (NCT04182490)